{"id":"W3088708979","doi":"10.1016/j.annonc.2020.08.058","title":"80TiP Global phase III study of NUC-1031 plus cisplatin vs gemcitabine plus cisplatin for first-line treatment of patients with advanced biliary tract cancer (NuTide:121)","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"ca_institutions":"Sunnybrook Health Science Centre; Princess Margaret Cancer Centre","funders":"FUJIFILM Toyama Chemical; Chugai Pharmaceutical; Genentech; Sirtex Medical; Ipsen; Daiichi Sankyo Europe; Servier; Sanofi; Kyowa Hakko Kirin; Eisai; Astellas Pharma; Pfizer; Incyte; NuCana; Agios Pharmaceuticals; Menarini Silicon Biosystems; Les Laboratories Pierre Fabre; Merck KGaA; Taiho Pharmaceutical; Amgen; Falk Foundation; Ariad Pharmaceuticals; Halozyme; Exelixis; G1 Therapeutics; Celgene; Bristol-Myers Squibb; Ono Pharmaceutical; Eli Lilly and Company; AstraZeneca","keywords":"Gemcitabine; Medicine; Tolerability; Cisplatin; Internal medicine; Oncology; Gallbladder cancer; Cancer; Phases of clinical research; Chemotherapy; Gastroenterology; Adverse effect","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001639662,0.001471406,0.002341993,0.0004559752,0.0003357913,0.001220294,0.001175001,0.001386568,0.008137069],"category_scores_gemma":[0.001023749,0.0007181728,0.002345047,0.0005478653,0.0009618683,0.0009796703,0.0005332998,0.004170494,0.001475139],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001103183,"about_ca_system_score_gemma":0.001826331,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002353075,"about_ca_topic_score_gemma":0.008638798,"domain_scores_codex":[0.9995121,0.0002803821,0.00002045229,0.00006831274,0.00003229901,0.00008639049],"domain_scores_gemma":[0.9992881,0.0001350929,0.0001248762,0.00005718444,0.00003727427,0.0003574457],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9103159,0.022817,0.00250302,0.0007648017,0.002231062,0.00005717074,0.0001122077,0.001372794,0.009042508,0.0002784602,0.004005361,0.04649988],"study_design_scores_gemma":[0.7782299,0.2090742,0.007223387,0.00004811454,0.001219134,0.00007055559,0.00005429334,0.0005798099,0.001031055,0.000160037,0.002280647,0.0000288195],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9832935,0.003744066,0.0005509675,0.001039121,0.0004830267,0.002354139,0.00334866,0.000161514,0.005025017],"genre_scores_gemma":[0.9704475,0.005627821,0.002737399,0.002351836,0.0003764606,0.002802541,0.006565812,0.0001292831,0.008961393],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008137069,"threshold_uncertainty_score":0.02722126,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09547658375415796,"score_gpt":0.4017426350863002,"score_spread":0.3062660513321422,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}